Companies › Nerviano Medical Sciences
3 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NMS-03305293 | – | Phase 1 | Small Cell Lung Cancer; Glioblastoma; Ovarian Cancer | Feb 2027 |
| atamparib PARP inhibitor | PARP1 | Phase 1 | NSCLC Adenocarcinoma | Jul 2028 |
| NMS-03597812 | – | Phase 1 | Relapsed/Refractory Acute Myeloid Leukemia | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06931626 | NMS-03305293 | Phase 1 | Small Cell Lung Cancer | Oncology | Feb 2027 |
| NCT04910022 | NMS-03305293 | Phase 1 | Glioblastoma | Oncology | May 2027 |
| NCT06930755 | NMS-03305293 | Phase 1 | Ovarian Cancer | Oncology | May 2027 |
| NCT07374419 | atamparib | Phase 1 | NSCLC Adenocarcinoma | Oncology | Jul 2028 |
| NCT06549790 | NMS-03597812 | Phase 1 | Relapsed/Refractory Acute Myeloid Leukemia | Oncology | Sep 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.